CD274 and neoplasm: The subgroup analysis of patients with a PD-L1 tumor area positivity of <1% (PD-L1-negative) or ≥1% (PD-L1-positive) showed similar benefits in both populations, again suggesting that baseline PD-L1 status may not be a useful biomarker for predicting the response to the addition of immunotherapy.